WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406325

CAS#: 593960-11-3

Description: PIK-93 is a potent PI3K inhibitor. PIK93 selectively inhibits the type III PI 4-kinase beta enzyme, and small interfering RNA-mediated down-regulation of the individual PI 4-kinase enzymes, revealed that PI 4-kinase beta has a dominant role in ceramide transport between the ER and Golgi.

Chemical Structure

CAS# 593960-11-3

Theoretical Analysis

MedKoo Cat#: 406325
Name: PIK-93
CAS#: 593960-11-3
Chemical Formula: C14H16ClN3O4S2
Exact Mass: 389.02708
Molecular Weight: 389.88
Elemental Analysis: C, 43.13; H, 4.14; Cl, 9.09; N, 10.78; O, 16.41; S, 16.45

Price and Availability

Size Price Availability Quantity
5.0mg USD 240.0 2 Weeks
25.0mg USD 610.0 2 Weeks
Bulk inquiry

Synonym: PIK93; PIK 93; PIK-93.

IUPAC/Chemical Name: N-(5-(4-chloro-3-(N-(2-hydroxyethyl)sulfamoyl)phenyl)-4-methylthiazol-2-yl)acetamide


InChi Code: InChI=1S/C14H16ClN3O4S2/c1-8-13(23-14(17-8)18-9(2)20)10-3-4-11(15)12(7-10)24(21,22)16-5-6-19/h3-4,7,16,19H,5-6H2,1-2H3,(H,17,18,20)

SMILES Code: CC(NC1=NC(C)=C(C2=CC=C(Cl)C(S(=O)(NCCO)=O)=C2)S1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition: 0– 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).

Solubility: soluble in DMSO

Shelf Life: >2 years if stored properly.

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 389.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1. Inhibitors of the PI3k/Akt/Ikk/NF-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for prophylaxis and treatment of viral diseases. By Fedichev, Petr Olegovich; Vinnik, Andrey Alexandrovich. From PCT Int. Appl. (2013), WO 2013147649 A2 20131003,

2. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. By Spickler, Catherine; Lippens, Julie; Laberge, Marie-Kristine; Desmeules, Sophie; Bellavance, Edith; Garneau, Michel; Guo, Tim; Hucke, Oliver; Leyssen, Pieter; Neyts, Johan; et al. From Antimicrobial Agents and Chemotherapy (2013), 57(7), 3358-3368. ,

3. Autoimmune and inflammatory disorder therapy using inhibitors of phosphatidylinositol-4-kinase IIIβ and screening methods thereof By Herman, Jean; Louat, Thierry; Huang, Qiuya; Vanderhoydonck, Bart; Waer, Mark; Herdewijn, Piet From PCT Int. Appl. (2013), WO 2013034738 A1 20130314,

4. Methods for predicting cancer treatment responsiveness to phosphatidylinositol 3-kinase (PI3K) inhibitors. By Jane, Stephen M.; Darido, Charbel. From PCT Int. Appl. (2013), WO 2013029116 A1 20130307,

5. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. By van der Schaar, Hilde M.; van der Linden, Lonneke; Lanke, Kjerstin H. W.; Strating, Jeroen R. P. M.; Puerstinger, Gerhard; de Vries, Erik; de Haan, Cornelis A. M.; Neyts, Johan; van Kuppeveld, Frank J. M. From Cell Research (2012), 22(11), 1576-1592. , DOI:10.1038/cr.2012.129

6. Methods for treating oncovirus positive cancers. By Jimeno, Antonio; Hausman, Diana F.; Peterson, Scott. From PCT Int. Appl. (2012), WO 2012118978 A1 20120907,

7. Methods and compositions targeting signaling pathways for the treatment of cancer By Brugge, Joan S.; Muranen, Taru; Mills, Gordon; Selfors, Laura. From PCT Int. Appl. (2011), WO 2011133668 A2 20111027,

8. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity By Arita, Minetaro; Kojima, Hirotatsu; Nagano, Tetsuo; Okabe, Takayoshi; Wakita, Takaji; Shimizu, Hiroyuki. From Journal of Virology (2011), 85(5), 2364-2372. , DOI:10.1128/JVI.02249-10

9. Modification of proteins for detection in cellular assays By Treiber, Daniel Kelly; Lewis, Warren G.; Wodicka, Lisa M. From PCT Int. Appl. (2010), WO 2010124157 A1 20101028,

10. Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34 By Miller, Simon; Tavshanjian, Brandon; Oleksy, Arkadiusz; Perisic, Olga; Houseman, Benjamin T.; Shokat, Kevan M.; Williams, Roger L. From Science (Washington, DC, United States) (2010), 327(5973), 1638-1642. ,

11. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α By Zunder, Eli R.; Knight, Zachary A.; Houseman, Benjamin T.; Apsel, Beth; Shokat, Kevan M. From Cancer Cell (2008), 14(2), 180-192. , DOI:10.1016/j.ccr.2008.06.014

12. Phosphoinositide modulation for the treatment of neurodegenerative diseases By Kim, Tae-Wan; Dipaolo, Gilbert; Kang, Min Suk; Berman, Diego; McIntire, Laura Beth Johnson From PCT Int. Appl. (2008), WO 2008064244 A2 20080529,

13. Design of Drug-Resistant Alleles of Type-III Phosphatidylinositol 4-Kinases Using Mutagenesis and Molecular Modeling By Balla, Andras; Tuymetova, Galina; Toth, Balazs; Szentpetery, Zsofia; Zhao, Xiaohang; Knight, Zachary A.; Shokat, Kevan; Steinbach, Peter J.; Balla, Tamas From Biochemistry (2008), 47(6), 1599-1607. , DOI:10.1021/bi7017927

14. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling By Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; et al From Cell (Cambridge, MA, United States) (2006), 125(4), 733-747. ,

15. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma . By Fan, Qi-Wen; Knight, Zachary A.; Goldenberg, David D.; Yu, Wei; Mostov, Keith E.; Stokoe, David; Shokat, Kevan M.; Weiss, William A. From Cancer Cell (2006), 9(5), 341-349.

16. 5-Phenylthiazole derivatives and their use as phosphatidylinositol 3-kinase (Pi3K) inhibitors for the treatment of allergic and inflammatory diseases. By Bruce, Ian; Finan, Peter; Leblanc, Catherine; McCarthy, Clive; Whitehead, Lewis; Blair, Nicola Elaine; Bloomfield, Graham Charles; Hayler, Judy; Kirman, Louise; Oza, Mrinalini Sachin; et al. From PCT Int. Appl. (2003), WO 2003072557 A1 20030904,


5.0mg / USD 240.0

Additional Information